No Data
No Data
Regeneron, Sanofi Get FDA Approval for Upper Airway Disease Treatment
Regeneron Pharmaceuticals And Sanofi Announce FDA Approval For Dupixent In The U.S. As First And Only Treatment For Adolescents With Chronic Rhinosinusitis With Nasal Polyps
Express News | Dupixent® (Dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents With Chronic Rhinosinusitis With Nasal Polyps (Crswnp)
Kiniksa Draws Buy at Jefferies on Potential Blockbuster Status for Lead Drug
Express News | Health Canada Has Issued A Notice Of Compliance For Sanofi/Regeneron Dupixent (Dupilumab Injection) For The Treatment Of Patients Aged 1 Year And Older, Weighing At Least 15 Kg, With Eosinophilic Esophagitis
BMO Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,300